EN 简
EN 简

Press Release

Media Inquiries

Brii Biosciences Announces First Subject Dosed in Phase 1 Clinical Trial of BRII-297, Long-Acting Injectable for the Treatment of Anxiety and Depressive Disorders

Jun 01, 2023

Brii Biosciences Announces Upcoming Investor Conferences Participation in June

May 31, 2023

Brii Bio Publishes 2022 Environmental, Social and Governance Report

Apr 28, 2023

Brii Biosciences Announces Upcoming Investor Conference Participation in May

Apr 27, 2023

Brii Biosciences Provides Corporate Update and Reports Full-Year 2022 Financial Results

Mar 24, 2023

Brii Biosciences Announces Interim Results from Phase 2 Study Evaluating Combination BRII-835 and BRII-179 in Development for HBV Functional Cure

Feb 15, 2023

Brii Biosciences Provides Update on Strategic Clinical Development Progress

Dec 27, 2022

Brii Biosciences Announces Upcoming Conference Participation in January

Dec 21, 2022

Brii Biosciences Announces Upcoming Conference Participation in November

Oct 28, 2022

Brii Biosciences Presents Promising Clinical Data to Support Ongoing Development of Novel HIV Therapeutic Candidates at IDWeek 2022

Oct 19, 2022

Brii Biosciences to Present New Phase 1 Data from HIV Program at IDWeek 2022

Oct 11, 2022

Brii Biosciences Announces Top-line Results from Phase 1 Study of BRII-296, A Long-Acting Therapy in Development for Postpartum Depression

Sep 26, 2022

Brii Biosciences Announces China Leadership Team Changes

Sep 02, 2022

Brii Biosciences Appoints Taiyin Yang to Board of Directors, Strengthening Product Quality Oversight to Support Company Momentum

Sep 01, 2022

Brii Biosciences Announces Upcoming Conference Participation in September

Aug 29, 2022

Brii Biosciences Provides Corporate Update and Reports 2022 Interim Results

Aug 24, 2022

Brii Biosciences Appoints Eleanor de Groot as Chief Technology Officer and Aleksandar Skuban as Central Nervous System Diseases Therapy Area Head

Aug 23, 2022

Brii Biosciences Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Live Omicron Virus BA.4/5 and BA.2.12.1 Subvariants

Jul 27, 2022

Brii Bio Announces Strategic Partnership with China Resources Pharmaceutical Commercial Group to Advance the Commercialization of Long-acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China

Jul 19, 2022

Brii Biosciences Appoints Dr. Susannah Cantrell as Chief Business Officer

Jul 13, 2022

Brii Biosciences Announces Commercial Launch of its Amubarvimab/Romlusevimab Combination Therapy for COVID-19 in China

Jul 07, 2022

Brii Biosciences Exercises Option for Vir Biotechnology’s VIR-3434, a Broadly Neutralizing Monoclonal Antibody Targeting Hepatitis B in Greater China

Jul 04, 2022

Brii Biosciences Announces Upcoming Conference Participation in July

Jun 30, 2022

Brii Biosciences Announces Positive Data from a Randomized, Single-Blind Study of its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China

Jun 09, 2022

Brii Bio Announces GMP Compliance Inspection Result for the Amubarvimab Injection and Romlusevimab Injection

May 31, 2022

Brii Biosciences Announces Upcoming Conference Participation in June

May 27, 2022

Brii Biosciences to be Added to MSCI China Small Cap Index

May 25, 2022

Brii Bio Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Omicron BA.2 Subvariant

May 09, 2022

Brii Bio Reports Progress on ESG Commitments in Its Inaugural ESG Report

May 07, 2022

Brii Biosciences Announces Upcoming Participation at May Conference

Apr 29, 2022

Brii Biosciences Announces Upcoming Participation at April Conferences

Apr 01, 2022

Brii Bio Presents New Data on BRII-835 (VIR-2218) in Chinese Patients with Chronic Hepatitis B at APASL 2022

Mar 31, 2022

Brii Bio Announces Strategic Partnership with Sinopharm to Advance Commercialization of Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China

Mar 30, 2022

Brii Biosciences Provides Corporate Update and Reports Full Year 2021 Financial Results

Mar 23, 2022

Brii Bio to Present Phase 2 Data on Two Monthly Doses of BRII-835 (VIR-2218) in Chinese Patients with Chronic Hepatitis B at APASL 2022

Mar 17, 2022

Brii Bio Announces that National Health Commission of China Adds Amubarvimab/Romlusevimab Combination to its COVID-19 Diagnosis and Treatment Guidelines (9th Pilot Edition)

Mar 16, 2022

Brii Biosciences Announces Upcoming Participation at March Conferences

Feb 28, 2022

Brii Bio Appoints Karen D. Neuendorff as Chief People Officer and Head of Human Resources

Jan 27, 2022

Brii Bio Doses First Patient in Phase 2a/2b Clinical Trial of BRII-179 (VBI-2601) for the Functional Cure of Chronic Hepatitis B

Dec 27, 2021

Brii Bio Announces Amubarvimab/Romlusevimab Combination Retains Neutralizing Activity Against Omicron SARS-CoV-2 Variant

Dec 12, 2021

Brii Biosciences Receives Clinical Hold Notification from US. FDA on BRII-732

Dec 12, 2021

Brii Bio Announces Amubarvimab/Romlusevimab Combination Received Approval from NMPA as First COVID-19 Neutralizing Antibody Combination Therapy in China

Dec 09, 2021

Brii Biosciences Included in Hong Kong Stock Connect

Dec 06, 2021

Brii Biosciences Joins Hang Seng Composite Index

Nov 19, 2021

Brii Bio Receives the BioCentury-BayHelix R&D Achievement of the Year Award at the 2021 BioCentury China Healthcare Summit

Nov 17, 2021

Brii Biosciences Announces Upcoming Participation at November Conferences

Oct 14, 2021

Brii Bio Initiates Submission of Emergency Use Authorization Filing to U.S. FDA for BRII-196/BRII-198, its Monoclonal Antibody Combination Therapy for Non-Hospitalized COVID-19 Patients at High Risk of Clinical Progression to Severe Disease

Oct 09, 2021

Brii Bio Presents Positive Phase 3 Data on BRII-196/BRII-198, the Company’s SARS-CoV-2 Monoclonal Neutralizing Antibody Combination Therapy, in an Oral Late-Breaker Presentation at IDWeek 2021

Oct 04, 2021

Brii Bio Appoints Coy Stout as Senior Vice President and Head of U.S. Market Access and Patient Advocacy

Sep 28, 2021

Brii Biosciences Adds US$100 Million to Advance its Late-Stage Monoclonal Antibody Combination Therapy, BRII-196/BRII-198, for Non-Hospitalized COVID-19 Patients

Sep 07, 2021

Brii Biosciences Announces Positive Data from the Phase 3 ACTIV-2 Trial Evaluating Combination BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients

Aug 25, 2021

Brii Biosciences Announces the Completion of Enrollment in the Phase 3 National Institutes of Health (NIH) ACTIV-2 Trial, Evaluating the BRII-196 and BRII-198 Monoclonal Neutralizing Antibody Combination for the Treatment of COVID-19

Aug 05, 2021

Brii Biosciences Initiates Phase 2 Clinical Trial in China for Neutralizing Antibodies, BRII-196 and BRII-198, in SARS-CoV-2

Jul 20, 2021

Brii Biosciences Limited Successfully Listed on Main Board of Hong Kong Stock Exchange

Jul 13, 2021

Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021

Jun 23, 2021

Brii Biosciences to Present Updated Phase 1b/2a Data on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021

Jun 09, 2021

Brii Biosciences Provides Update on Strategic Clinical Development Progress

May 17, 2021

Brii Biosciences Monoclonal Antibodies, BRII-196 and BRII-198, Progress to Phase 3 in NIH ACTIV-2 Trial in Ambulatory COVID-19 Patients

Apr 29, 2021

Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B

Apr 21, 2021

Brii Biosciences Closes US$155 Million Series C Financing

Mar 23, 2021

Brii Biosciences Antibody Combination Will Not Progress into a Phase 3 Study Evaluating the Treatment of SARS-CoV-2 in Hospitalized Patients

Mar 03, 2021

Brii Biosciences Provides Corporate Update on Progress Against Strategic R&D Priorities

Dec 17, 2020

Brii Biosciences Appoints Rogers Luo, Ankang Li To Leadership Positions

Sep 17, 2020

Tsinghua University, 3rd People’s Hospital of Shenzhen and Brii Biosciences Establish Partnership to Develop Neutralizing Antibodies Against COVID-19

Mar 31, 2020

Brii Biosciences Provides Funding to Columbia University for Research on COVID-19 and Other Coronaviruses

Mar 11, 2020

Brii Biosciences Expands Therapeutic Focus to Include Neurosciences with Addition of John Kraus, M.D., Ph.D.

Dec 03, 2019

Brii Biosciences Expands Infectious Disease Pipeline

Nov 21, 2019

VBI Vaccines and Brii Biosciences Initiate Phase 1b/2a Study of BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B Infection

Nov 14, 2019

WuXi Biologics Announced Exclusive Discovery Research with Brii Biosciences for Novel Bispecific Antibody Immunotherapeutics

Dec 11, 2018

Brii Biosciences Builds Innovative Pipeline, Forges Public-Private Partnerships to Bring Novel Medicines to Chinese Patients

Dec 06, 2018

FierceBiotech names Brii Biosciences as one of its “Fierce 15” Biotech Companies of 2018

Oct 02, 2018

Brii Biosciences Launches to Bring Innovative Medicines to Chinese Patients

May 24, 2018

Brii Biosciences Announces First Subject Dosed in Phase 1 Clinical Trial of BRII-297, Long-Acting Injectable for the Treatment of Anxiety and Depressive Disorders

Jun 01, 2023

Brii Biosciences Announces Upcoming Investor Conferences Participation in June

May 31, 2023

Brii Bio Publishes 2022 Environmental, Social and Governance Report

Apr 28, 2023

Brii Biosciences Announces Upcoming Investor Conference Participation in May

Apr 27, 2023

Brii Biosciences Provides Corporate Update and Reports Full-Year 2022 Financial Results

Mar 24, 2023

Brii Biosciences Announces Interim Results from Phase 2 Study Evaluating Combination BRII-835 and BRII-179 in Development for HBV Functional Cure

Feb 15, 2023

Brii Biosciences Provides Update on Strategic Clinical Development Progress

Dec 27, 2022

Brii Biosciences Announces Upcoming Conference Participation in January

Dec 21, 2022

Brii Biosciences Announces Upcoming Conference Participation in November

Oct 28, 2022

Brii Biosciences Presents Promising Clinical Data to Support Ongoing Development of Novel HIV Therapeutic Candidates at IDWeek 2022

Oct 19, 2022

Brii Biosciences to Present New Phase 1 Data from HIV Program at IDWeek 2022

Oct 11, 2022

Brii Biosciences Announces Top-line Results from Phase 1 Study of BRII-296, A Long-Acting Therapy in Development for Postpartum Depression

Sep 26, 2022

Brii Biosciences Announces China Leadership Team Changes

Sep 02, 2022

Brii Biosciences Appoints Taiyin Yang to Board of Directors, Strengthening Product Quality Oversight to Support Company Momentum

Sep 01, 2022

Brii Biosciences Announces Upcoming Conference Participation in September

Aug 29, 2022

Brii Biosciences Provides Corporate Update and Reports 2022 Interim Results

Aug 24, 2022

Brii Biosciences Appoints Eleanor de Groot as Chief Technology Officer and Aleksandar Skuban as Central Nervous System Diseases Therapy Area Head

Aug 23, 2022

Brii Biosciences Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Live Omicron Virus BA.4/5 and BA.2.12.1 Subvariants

Jul 27, 2022

Brii Bio Announces Strategic Partnership with China Resources Pharmaceutical Commercial Group to Advance the Commercialization of Long-acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China

Jul 19, 2022

Brii Biosciences Appoints Dr. Susannah Cantrell as Chief Business Officer

Jul 13, 2022

Brii Biosciences Announces Commercial Launch of its Amubarvimab/Romlusevimab Combination Therapy for COVID-19 in China

Jul 07, 2022

Brii Biosciences Exercises Option for Vir Biotechnology’s VIR-3434, a Broadly Neutralizing Monoclonal Antibody Targeting Hepatitis B in Greater China

Jul 04, 2022

Brii Biosciences Announces Upcoming Conference Participation in July

Jun 30, 2022

Brii Biosciences Announces Positive Data from a Randomized, Single-Blind Study of its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China

Jun 09, 2022

Brii Bio Announces GMP Compliance Inspection Result for the Amubarvimab Injection and Romlusevimab Injection

May 31, 2022

Brii Biosciences Announces Upcoming Conference Participation in June

May 27, 2022

Brii Biosciences to be Added to MSCI China Small Cap Index

May 25, 2022

Brii Bio Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Omicron BA.2 Subvariant

May 09, 2022

Brii Bio Reports Progress on ESG Commitments in Its Inaugural ESG Report

May 07, 2022

Brii Biosciences Announces Upcoming Participation at May Conference

Apr 29, 2022

Brii Biosciences Announces Upcoming Participation at April Conferences

Apr 01, 2022

Brii Bio Presents New Data on BRII-835 (VIR-2218) in Chinese Patients with Chronic Hepatitis B at APASL 2022

Mar 31, 2022

Brii Bio Announces Strategic Partnership with Sinopharm to Advance Commercialization of Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China

Mar 30, 2022

Brii Biosciences Provides Corporate Update and Reports Full Year 2021 Financial Results

Mar 23, 2022

Brii Bio to Present Phase 2 Data on Two Monthly Doses of BRII-835 (VIR-2218) in Chinese Patients with Chronic Hepatitis B at APASL 2022

Mar 17, 2022

Brii Bio Announces that National Health Commission of China Adds Amubarvimab/Romlusevimab Combination to its COVID-19 Diagnosis and Treatment Guidelines (9th Pilot Edition)

Mar 16, 2022

Brii Biosciences Announces Upcoming Participation at March Conferences

Feb 28, 2022

Brii Bio Appoints Karen D. Neuendorff as Chief People Officer and Head of Human Resources

Jan 27, 2022

Brii Bio Doses First Patient in Phase 2a/2b Clinical Trial of BRII-179 (VBI-2601) for the Functional Cure of Chronic Hepatitis B

Dec 27, 2021

Brii Bio Announces Amubarvimab/Romlusevimab Combination Retains Neutralizing Activity Against Omicron SARS-CoV-2 Variant

Dec 12, 2021

Brii Biosciences Receives Clinical Hold Notification from US. FDA on BRII-732

Dec 12, 2021

Brii Bio Announces Amubarvimab/Romlusevimab Combination Received Approval from NMPA as First COVID-19 Neutralizing Antibody Combination Therapy in China

Dec 09, 2021

Brii Biosciences Included in Hong Kong Stock Connect

Dec 06, 2021

Brii Biosciences Joins Hang Seng Composite Index

Nov 19, 2021

Brii Bio Receives the BioCentury-BayHelix R&D Achievement of the Year Award at the 2021 BioCentury China Healthcare Summit

Nov 17, 2021

Brii Biosciences Announces Upcoming Participation at November Conferences

Oct 14, 2021

Brii Bio Initiates Submission of Emergency Use Authorization Filing to U.S. FDA for BRII-196/BRII-198, its Monoclonal Antibody Combination Therapy for Non-Hospitalized COVID-19 Patients at High Risk of Clinical Progression to Severe Disease

Oct 09, 2021

Brii Bio Presents Positive Phase 3 Data on BRII-196/BRII-198, the Company’s SARS-CoV-2 Monoclonal Neutralizing Antibody Combination Therapy, in an Oral Late-Breaker Presentation at IDWeek 2021

Oct 04, 2021

Brii Bio Appoints Coy Stout as Senior Vice President and Head of U.S. Market Access and Patient Advocacy

Sep 28, 2021

Brii Biosciences Adds US$100 Million to Advance its Late-Stage Monoclonal Antibody Combination Therapy, BRII-196/BRII-198, for Non-Hospitalized COVID-19 Patients

Sep 07, 2021

Brii Biosciences Announces Positive Data from the Phase 3 ACTIV-2 Trial Evaluating Combination BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients

Aug 25, 2021

Brii Biosciences Announces the Completion of Enrollment in the Phase 3 National Institutes of Health (NIH) ACTIV-2 Trial, Evaluating the BRII-196 and BRII-198 Monoclonal Neutralizing Antibody Combination for the Treatment of COVID-19

Aug 05, 2021

Brii Biosciences Initiates Phase 2 Clinical Trial in China for Neutralizing Antibodies, BRII-196 and BRII-198, in SARS-CoV-2

Jul 20, 2021

Brii Biosciences Limited Successfully Listed on Main Board of Hong Kong Stock Exchange

Jul 13, 2021

Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021

Jun 23, 2021

Brii Biosciences to Present Updated Phase 1b/2a Data on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021

Jun 09, 2021

Brii Biosciences Provides Update on Strategic Clinical Development Progress

May 17, 2021

Brii Biosciences Monoclonal Antibodies, BRII-196 and BRII-198, Progress to Phase 3 in NIH ACTIV-2 Trial in Ambulatory COVID-19 Patients

Apr 29, 2021

Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B

Apr 21, 2021

Brii Biosciences Closes US$155 Million Series C Financing

Mar 23, 2021

Brii Biosciences Antibody Combination Will Not Progress into a Phase 3 Study Evaluating the Treatment of SARS-CoV-2 in Hospitalized Patients

Mar 03, 2021

Brii Biosciences Provides Corporate Update on Progress Against Strategic R&D Priorities

Dec 17, 2020

Brii Biosciences Appoints Rogers Luo, Ankang Li To Leadership Positions

Sep 17, 2020

Tsinghua University, 3rd People’s Hospital of Shenzhen and Brii Biosciences Establish Partnership to Develop Neutralizing Antibodies Against COVID-19

Mar 31, 2020

Brii Biosciences Provides Funding to Columbia University for Research on COVID-19 and Other Coronaviruses

Mar 11, 2020

Brii Biosciences Expands Therapeutic Focus to Include Neurosciences with Addition of John Kraus, M.D., Ph.D.

Dec 03, 2019

Brii Biosciences Expands Infectious Disease Pipeline

Nov 21, 2019

VBI Vaccines and Brii Biosciences Initiate Phase 1b/2a Study of BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B Infection

Nov 14, 2019

WuXi Biologics Announced Exclusive Discovery Research with Brii Biosciences for Novel Bispecific Antibody Immunotherapeutics

Dec 11, 2018

Brii Biosciences Builds Innovative Pipeline, Forges Public-Private Partnerships to Bring Novel Medicines to Chinese Patients

Dec 06, 2018

FierceBiotech names Brii Biosciences as one of its “Fierce 15” Biotech Companies of 2018

Oct 02, 2018

Brii Biosciences Launches to Bring Innovative Medicines to Chinese Patients

May 24, 2018